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Abstract
Background: The gram-negative bacterium Francisella tularensis survives in arthropods, fresh water amoeba, and mammals
with both intracellular and extracellular phases and could reasonably be expected to express distinct phenotypes in these
environments. The presence of a capsule on this bacterium has been controversial with some groups finding such a
structure while other groups report that no capsule could be identified. Previously we reported in vitro culture conditions
for this bacterium which, in contrast to typical methods, yielded a bacterial phenotype that mimics that of the bacterium’s
mammalian, extracellular phase.
Methods/Findings: SDS-PAGE and carbohydrate analysis of differentially-cultivated F. tularensis LVS revealed that bacteria
displaying the host-adapted phenotype produce both longer polymers of LPS O-antigen (OAg) and additional HMW
carbohydrates/glycoproteins that are reduced/absent in non-host-adapted bacteria. Analysis of wildtype and OAg-mutant
bacteria indicated that the induced changes in surface carbohydrates involved both OAg and non-OAg species. To assess
the impact of these HMW carbohydrates on the access of outer membrane constituents to antibody we used differentially-
cultivated bacteria in vitro to immunoprecipitate antibodies directed against outer membrane moieties. We observed that
the surface-carbohydrates induced during host–adaptation shield many outer membrane antigens from binding by
antibody. Similar assays with normal mouse serum indicate that the induced HMW carbohydrates also impede complement
deposition. Using an in vitro macrophage infection assay, we find that the bacterial HMW carbohydrate impedes TLR2-
dependent, pro-inflammatory cytokine production by macrophages. Lastly we show that upon host-adaptation, the human-
virulent strain, F. tularensis SchuS4 also induces capsule production with the effect of reducing macrophage-activation and
accelerating tularemia pathogenesis in mice.
Conclusion: F. tularensis undergoes host-adaptation which includes production of multiple capsular materials. These
capsules impede recognition of bacterial outer membrane constituents by antibody, complement, and Toll-Like Receptor 2.
These changes in the host-pathogen interface have profound implications for pathogenesis and vaccine development.
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Introduction
Francisella tularensis is an extremely infectious gram-negative
bacterium which is readily aerosolized. Inhalation of this Category
A select agent can lead to pulmonary tularemia which has a
mortality rate of ,35% in the absence of treatment. Reportedly,
antibiotic-resistant strains of this bacterium were developed by at
least one nation’s biological weapons program [1]. The specter of
such an agent being maliciously employed, in concert with the
current lack of a licensed tularemia vaccine, has evoked a ground
swell of interest in F. tularensis.
In addition to being a potentially fearsome biological weapon, F.
tularensis also is a naturally-occurring zoonotic bacterium found in
strikingly diverse environments including an array of warm- and
cold-blooded hosts (mammals, insects, arthropods, fresh water
protozoans) [1,2]. The tularensis subspecies (ssp., comprised of type
A strains and found in North America) is maintained primarily in a
terrestrial cycle involving lagomorphs and rodents with transmis-
sion via ticks and tabanid (deer, horse, etc) flies. In contrast, the
holartica ssp. (type B strains which are distributed throughout the
northern hemisphere) has a stronger association with water-borne
disease and, perhaps consequently, with transmission by mosqui-
toes (as well as ticks and biting flies). In addition to the broad range
of hosts, it has recently become appreciated that within both
mammalian and protozoan infection models, the bacterium has
both intracellular (replicative) and extracellular (transmissive)
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bacterium must adapt. Furthermore, a growing body of evidence
indicates that as F. tularensis progresses through the intracellular
cycle (phagocytosis and phagosomal escape, cytoplasmic replica-
tion, induction of autophagic vacuoles and cellular escape) the
bacterium adapts to distinct micro-environments by modulating
expression of many genes [8–10].
The mutability of this bacterium, which endows such a broad
host range, also poses a challenge to vaccine development as the
nature of the inoculum (with potentially distinct antigenic
compositions) can vary widely. Upon entering the mammalian
environment the bacterium will presumably adapt regardless of its
immediate history. However, it must be considered that the time
required for complete bacterial adaptation of a F. tularensis inoculum
is currentlyunknown - asistheimpact that this adaptionmighthave
on tularemia vaccination strategies. A salient example of how
bacterial adaptation can affect vaccination against vector-borne
pathogens is provided by the now defunct LYMErix vaccine that
induced antibody (Ab) against OspA of Borrelia burgdorferi, the tick-
borne Lyme disease spirochete. This vaccine was developed largely
based on work with non-host-adapted bacteria in which OspA was
characterized as an abundant, surface-exposed outer membrane
protein which could serve as a protective antigen in syringe-
inoculation models of murine borreliosis. After many years of
development and commitment of financial resources, it was
subsequently revealed that, to be effective, the host’s bacteriocidal
a–OspA Ab had to enter the feeding tick early in the blood meal to
kill the tick-adapted spirochete. This was necessary because, in
preparation for exiting the tick and entering the mammalian host,
the bacterium dramatically down-regulates expression of OspA.
Consequently, any host-adapted (OspA negative) spirochetes that
entered the host were ‘‘immune’’ to the host’s vaccine-induced
immunity [11], an observation which correlated well with the
vaccine’s sub-optimal efficacy. Production of LYMErix was halted
in 2002. The desire to work with host-adapted F. tularensis as a
platform for vaccine-discovery prompted our previous efforts to
recapitulate the bacterium’s mammal-adapted phenotype during in
vitro growth [12].
As F. tularensis replicates within host cells, cell-mediated
immunity has long been considered paramount to the control of
disease. However, the growing recognition that the bacterium has
a significant extracellular phase [4,5,7] provides a mechanistic
explanation for the early observation that adoptively-transferred
immune serum provides a degree of protection [13]. This original
report has been confirmed and extended under more defined
experimental conditions/infection models using both the attenu-
ated type B, live vaccine strain (LVS) [14-19] and the human-
virulent, Type A strain SchuS4 [20,21] as challenge inoculums. It
should be noted, however, that none of these more recent
challenges were initiated with host-adapted bacteria. Where
therapeutic administration of either immune serum or Ag-specific
Ab has been examined, the serum/Ab’s full therapeutic potential
was realized by administration beginning no-later than 24 hr post-
infection (PI) [16,20,22]; further delays in Ab-therapy (potentially
allowing for further bacterial adaptation) result in dramatic
reductions and/or loss of transferrable protection [16]. Consistent
with this susceptibility of non-host-adapted bacteria to Ab, it has
recently been shown that animals receiving multiple transfers of
immune serum (on days 21, +3, +6, +9, and +12 relative to
challenge on day zero) are no more protected from challenge than
animals that receive a single equal dose of immune serum one day
before infection [21].
In addition prophylactic and/or therapeutic approaches
involving immunization with attenuated/inactivated bacteria
and/or adaptive transfer of serum/Ab, several purified or semi-
purified antigens have been assessed as sub-unit vaccine
candidates. Perhaps the most well-characterized is lipopolysac-
cahride (LPS) which in gram-negative bacterium is readily
antibody-accessible – provided the bacterium is not heavily
encapsulated. Preparations of F. tularensis LPS (a poor TLR4
agonist) have been shown to be protective immunogens by
multiple groups [23–28]. However, as we and others [25,29] have
observed, the most widely-cited method for preparing LPS from
this bacterium (hot-phenol extraction) also co-purifies a significant
amount of HMW carbohydrate/putative capsule; this material can
amount to 40% of the total ‘‘LPS’’ preparation [25]. This raises
the specter that some of the protection ascribed to LPS
immunization may, in part, represent anti-capsule responses.
Indeed a recent report showed that active immunization with OAg
capsule or passive immunization with a mAb directed against the
capsular OAg was protective [30].
Our long term interests include the identification of bacterial
surface proteins which are both i) accessible to host antibodies
and/or cellular receptors and, importantly, ii) are expressed
during mammalian infection. In support of this goal we previously
identified in vitro culture conditions that recapitulate the bacter-
ium’s mammalian host-adapted, extracellular phenotype. Here we
describe the further pursuit of our objective which has led us to the
discovery that host-adaptation includes multiple changes to the
bacterium’s surface carbohydrates (LPS and capsules) which
cumulatively hinder recognition of OM constituents by Ab,
complement, and TLR2.
Results
Francisella tularensis grown in brain-heart infusion broth
display the bacterium’s extra cellular, host-adapted
phenotype
Host-adapted F. tularensis (those replicating in macrophages or in
the tissues of mice) display a phenotype distinct from that of
bacteria cultivated in vitro using standard media such as in Mueller
Hinton broth (MHB) or Chamberlain’s defined media (CDM)
[31,32]. The phenotypic differences include expression of a
distinct bacterial proteome as well as the elicitation of a different
reaction from naı ¨ve macrophages (MW) responding to the bacteria
[33]. Recently we reported that growth of F. tularensis in BHI
induces a phenotype that is indistinguishable from that of bacteria
which have emerged from infected MW (i.e. extracellular, host-
adapted F. tularensis) [12]. This work was undertaken in support of
our longer-term goal: the direct biochemical identification of
surface-exposed, outer membrane (OM) proteins (OMPs) which
are expressed during mammalian infection. As candidates for a
sub-unit vaccine, such proteins could serve as targets for antibody
(Ab) during the bacterium’s extra-cellular phase [5,7].
Here, prior to commencing our quest for such OMPs, we first
sought to confirm and extend the notion that growth of F. tularensis
in BHI induces the bacterium’s host-adapted phenotype. To this
end we used western blot analysis of several differentially-
expressed proteins to gauge the similarity between MHB-, BHI-,
and extracellular, MW-grown F. tularensis. To extend our
understanding of the regulatory genes and environmental cues
which govern host-adaption we also probed BHI-grown, mglA and
pmrA strains along with wildtype (WT) F. tularensis grown in the
presence of high concentrations of free amino acids [12] (in the
form of casamino acids - CA) or spermine [34]. As shown in Fig 1,
F. tularensis that have emerged from infected MW and those which
were grown in BHI contain similarly elevated levels of the
Intracellular Growth Locus (Igl) proteins B and C, catalase (KatG),
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were minimally-expressed by F. tularensis grown in MHB (which
contains 17.5 g/l casamino acids) or in BHI supplemented with
casamino acids to 17.5 g/l (BCA). These protein changes during
host-adaptation were entirely dependent on the transcriptional
regulator MglA (a homologue of the E. coli stringent starvation
protein SspA [37] which responds to amino-acid deprivation [38]).
MglA activates transcription of the Igls and represses that of KatG
[39]. PmrA had a detectable, but less pronounced, contribution to
these regulatory changes. Supplementation of MHB with spermine
(MS), which induces multiple transcriptional changes in F. tularensis
[34], had minimal impact on the abundance of these proteins.
The quest for outer membrane proteins in host-adapted
F. tularensis reveals putative capsular material(s)
To aid our search for differentially-expressed OMPs we
fractionated MHB- and BHI-grown F. tularensis using Triton X-
114 (Tx) phase-partitioning [40,41,42,43] combined with differ-
ential membrane solubilization of the Triton-insoluble material.
To validate this approach, the resulting fractions along with the
parental whole cell lysates (WC) were probed with antisera specific
for proteins of known or predicted location. Consistent with
previous reports of IglA, IglB, IglC, and GroEL (a chaperone) and
KatG being soluble cytoplasmic and periplasmic proteins
respectively [31,44–46], we found that these species quantitatively
partition into the Tx-aqueous (A) phases (Fig 2A). Curiously, KatG
and GroEL along with SodB (superoxide dismutase) and Bfr
(a bacterioferritn homolog) have also been found in the culture
supernatants of non-host-adapted F. tularensis [47,48]. Active
secretion of the bacterial antioxidant enzymes into host cells could
limit cellular activation by altering redox-dependent host cell
signaling [49]. Given the alterations of KatG and SodB expression
we observed in host-adapted F. tularensis (Fig 1 and reference [12]),
we quantitatively assessed the distribution of KatG, GroEL, SodB,
and Bfr in MHB- and BHI-grown cells and cell-free supernatants.
To aid the interpretation of our findings, we similarly analyzed the
distribution of the E. coli a–hemolysin (HlyA), a secreted pore-
forming protein [50,51] whose expression is increased during
mammalian infection [52,53]. As expected for a secreted protein,
HlyA was readily detected (96–97% of the total) in the culture
supernatants of E. coli with only scant levels observed within the
bacterial cells (Fig. S1). In stark contrast, the F. tularensis proteins
were readily detected in bacterial cells with only scant amounts
(,1% of the total) detected in the supernatants and only those of
MHB-grown F. tularensis. Based on these findings, we conclude
that these F. tularensis proteins are not actively secreted - consistent
with the findings of Hager et. al. for LVS [54]. A similar
controversy over the active secretion of catalase, chaperones,
superoxide dismutase, peroxiredoxins, and others played out in the
Mycobacterium tuberculosis field in the 1990s including notions of how
these bacterial enzymes could modify host cell behavior [55-59].
Ultimately, active secretion of these Mtb proteins (and presumably
their effector functions within host cells) was unambiguously
disproven by Tullius et. al. who used approaches similar to those
used here to show that the presence of these proteins in cell-free
culture supernatants resulted, not from active secretion, but
instead from bacterial cell lysis in concert with the high abundance
and extra-cellular stability of these proteins [60].
Of the membrane proteins, FsaP contains a single internal,
transmembrane domain [61] which would place it in the
cytoplasmic membrane [62,63], a location consistent with both
our detection of FsaP in the Tx-detergent phases (which lack the
OM markers FopA, TolC, and LPS OAg, Fig 2A) and the inability
of polyclonal FsaP-specific Ab to label the surfaces of either intact
F. tularensis or recombinant E. coli expressing FsaP [61]. While
Figure 1. F. tularensis grown in MW or in BHI are nearly
indistinguishable. F. tularensis LVS strains were harvested from the
culture supernatants of infected macrophages (MW) or grown in vitro as
indicated: MHB (M), BHI (B), MHB supplemented with spermine to
200 mM (MS), BHI supplemented with casamino acids to 17.5 g/L (BCA).
Ten micrograms of protein from these bacteria were resolved by SDS-
PAGE and transferred to membranes for western blot analysis with
antibodies specific to the indicated proteins.
doi:10.1371/journal.pone.0022335.g001
Figure 2. Fractionation of F. tularensis reveals the presence of
an inducible HMW carbohydrate in host-adapted bacteria.
Whole cells (WC) of MHB- (M) and BHI-(B) grown F. tularensis LVS were
Tx114 phase-partitioned into aqueous (A), detergent (D), and Tx-
insoluble phases. The insoluble material was treated with 0.2% sarkosyl
to generate soluble (SS) and insoluble (SI) fractions. A) Intact fractions
derived from 10 mg of WC protein were probed by western blot for the
indicated proteins. Predicted locations were derived from the LVS
protein sequence with the aid of PSORT (http://psort.hgc.jp/form.html).
B) Carbohydrates present in proteinase K-treated fractions derived from
10 mg of WC protein were visualized by Emerald Green staining of
resolved samples.
doi:10.1371/journal.pone.0022335.g002
Host-Adaptation Shields Ft from Immune Effectors
PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22335contrary to the interpretations of Mellio et. al. [61], our assignment
of FsaP to the inner membrane is also consistent with the protein’s
lack of heat-modifiability – a characteristic property of membrane-
spanning OM proteins [62] – displayed by FopA but not FsaP
(data not shown). Pal (peptidoglycan-associated lipoprotein) and
Tul4 (as known as LpnA) are predicted and confirmed lipoproteins
respectively [45,64]. As the rules for lipoprotein sorting in F.
tularensis have not been established [45], it is not yet possible to
predict with confidence the location of these molecules which
could be lipid anchored to i) the outer leaflet of the inner
membrane, ii) the inner leaflet of the outer membrane, or iii) the
outer leaflet of the outer membrane [65]. Pal homologues in gram-
negative bacteria are sub-surface moieties anchored by their N-
terminal lipids to the inner leaflet of the OM allowing the protein
to bind the periplasmic peptidoglycan [65]. Tul4 is a potent TLR2
agonist [66,67] which is reportedly surface-exposed in capsule-
deficient F. tularensis but not in the WT bacteria [68]. These
cellular locations are consistent with our detection of the
lipoproteins primarily in the Tx detergent (D) phases and, to a
lesser extent, the Tx-insoluble, sarkysol-soluble (SS) phases
(Fig 2A). TolC-B and FopA are well characterized membrane-
spanning OMPs [69] and as expected, we detected these proteins
in the sarkosyl-insoluble (SI) fraction (Fig 2A).
As a final means of validating our approach, we analyzed these
same fractions (after proteinase-K treatment) by SDS-PAGE
followed by periodic acid oxidation and fluorescent staining to
visualize carbohydrates such as those in LPS - a known OM
constituent. As expected, the typical ladder pattern of repeating
LPS O-antigen (OAg) units was observed in the WC and SI
fractions but not in the A, D, or SS phases (Fig. 2B). However, this
carbohydrate staining also revealed unexpected and striking
differences between MHB and BHI-grown F tularensis.
First, despite equivalent amounts of Lipid A core, the ‘‘short’’
LPS (containing one to three OAg repeats) was more abundant in
MHB-grown bacteria whereas the LPS from BHI-grown F
tularensis was more heavily populated by ‘‘long’’ LPS (see Fig. 2B
and Fig. S2 for long and short exposures of the same gel). The
increased abundance of ‘‘short’’ LPS in MHB-grown F. tularensis
was confirmed by western blots (data not shown) with mAb FB11
which is specific for the bacterium’s LPS OAg [30]. Another
significant difference was apparent in the high-molecular weight
(HMW) carbohydrates of MHB- and BHI-grown F. tularensis. The
MHB WC samples contained a diffuse region of staining
extending roughly from ,100 kDa to slightly above 225 kDa
(Fig 2B). In the BHI-grown samples, this region of staining
extended well above the 225 kDa marker to nearly the bottom of
the loading wells. Upon phase-partitioning, this BHI-specific
$225 kDa carbohydrate was found in the aqueous phase along
with a BHI-specific, protease-resistant, ,200 kDa putative
glycoprotein that is labeled by both carbohydrate- and protein-
specific stains (Fig S3). The phase-partitioning behavior of the
HMW carbohydrate was similar to that of the F. tularensis OAg
capsule recently described by Apicella et. al. [30]. As both capsules
and extended-length LPS molecules can markedly impact the
accessibility of OMPs [70,71], we next sought to determine if host-
adaptation of F. tularensis alters the production of OAg capsule
and/or the accessibility of Ab to OM constituents.
Host-adapted F. tularensis produce more OAg capsule
and bind less Ab directed against OM constituents
To probe the surface of F. tularensis for OAg capsule and OM
accessibility we incubated intact bacteria with various Ab and
probed the washed bacteria for bound immunoglobulin heavy
chain (HC) by western blot. Following development of the Ig HC
signals, we re-probed the membranes for total FopA and
quantified the data as surface Ab/total FopA and normalized
the ratios to the corresponding MHB result. As shown in Fig. 3A
and B, when F. tularensis was incubated with immune mouse serum
(IMS) the amount of IgG bound to the surface of BHI-grown, WT
F. tularensis was significantly reduced relative to that of its MHB-
grown counterpart. The amount of IgG bound to the surface of
MHB-grown, WT F. tularensis and the BHI-grown, OAg mutant
was not significantly different (Fig 3B) and there were no
Figure 3. Host-adapted F. tularensis produce more OAg capsule
and bind less Ab directed against OM constituents. A) Intact
bacteria (WT and wbtA), grown in MHB (M) or BHI (B), were incubated
with the indicated sera/Ab, washed and probed for IgG heavy chain by
western blot. The probed membranes were stripped and re-probed for
total signals for the indicated proteins. B) Surface-bound Ab-to-FopA
ratios from 5–8 independent experiments were quantified and
expressed relative to that of the MHB-grown WT with same Ab.
Asterisks indicate values that differed significantly (p#0.05, T-test with
Bonferonni correction). C) MHB- and MW- grown F. tularensis were
incubated with Ab specific for the OAg-capsule and Tul4 and analyzed
as in A above. Mean FopA-normalized, surface Ab values from 3
independent experiments are indicated along with standard deviations
in parentheses.
doi:10.1371/journal.pone.0022335.g003
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of these three bacteria (Fig 3B).
The trend of Ab binding significantly better to the surfaces of
MHB-grown F. tularensis also was observed with Ab specific for
Tul4A, FopA, and LPS OAg (Figs 3A and 3B). This trend,
however, was reversed when we probed MHB- and BHI-grown F.
tularensis with Ab specific for the OAg capsule. BHI-grown F.
tularensis bound 3-fold more a-OAg capsule Ab than did the same
bacterium grown in MHB. MW-grown F. tularensis also displayed
increased production of OAg capsule and reduced OMP (Tul4)
accessibility compared to the non-host-adapted bacteria (Fig 3C).
As with the BHI-grown bacteria, the reduced Ab binding was not
explained by a reduction in Ag expression.
While the increased levels of OAg capsule and reduced
accessibly of Ab to OM constituents noted in Fig 3 were
internally-consistent, the ,3-fold increase in OAg capsule
observed with BHI-grown F. tularensis seemed disproportionate
to the 60–95% reduction in binding of a–OMP Ab by the same
cells. Additionally, removal of the OAg capsule (in BHI-grown
wbtA) did not, in all cases, fully restore Ab binding to the levels
observed with MHB-grown bacteria. For these two reasons, we
postulated that host-adapted F. tularensis might produce an
additional capsule-like material.
Host-adapted F. tularensis produce an additional high
molecular weight carbohydrate that also correlates with
reduced accessibility of Ab to OMPs
To determine if growth in BHI induced production of a
HMW carbohydrate in addition to OAg capsule we examined
the carbohydrate composition of MHB- and BHI-grown wbtA F.
tularensis. As shown in Fig 4A, the BHI-grown, wbtA strain
produced far more HMW carbohydrate than its MHB-grown
counterpart. This HMW carbohydrate was similar in size
(.225 kDa) to the material present in WT, BHI-grown F.
tularensis. Upon phase-partitioning this material, along with the
,200 kDa putative glycoprotein, was found in the aqueous
phase (Fig S3) similar to what was observed for WT BHI-grown
F. tularensis (Fig 2B). The aqueous-phase, HMW carbohydrate
material derived from BHI-grown, WT F. tularensis was slightly
more abundant than that of the BHI-grown, wbtA mutant
(Fig S3) likely indicating that the WT HMW carbohydrate
material contains both OAg capsule and the non-OAg HMW
carbohydrate.
To determine if the presence of this non-OAg, BHI-specific
material correlated with reduced binding of a–OMP Ab, we used
MHB- and BHI-grown WT and wbtA F. tularensis to immuno-
precipitate a-Tul4A and a-FopA Ab as was done for Fig 3. As
expected, the wbtA strain bound more a–OMP Ab than the
similarly grown WT strain. However even in the absence of OAg,
BHI-grown wbtA bound significantly less surface Ab than its MHB-
grown, wbtA counterpart (Fig 4B and 4C). This diminished binding
could not be explained by differences in loading or Ag expression
(data not shown), but could be explained by the BHI-specific,
HMW carbohydrate shielding the OMPs from Ab.
Host-adaptation reduces interaction with effectors of
innate immunity
Since the access of many OM constituents to Ab was reduced in
host-adapted F. tularensis, we postulated that OM constituents
might also be shielded from elements of the innate immune
system. We tested this notion in vitro by examining the ability of
differentially-grown bacteria to promote i) complement deposition
and ii) TLR2-dependent cellular activation of naı ¨ve MWs.
As a respiratory and blood-borne pathogen, F. tularensis would
be exposed to complement during the bacterium’s extra-cellular
phase within mammalian hosts [72]. Since LPS- and/or capsule-
mutants of F. tularensis fix complement more readily than WT
bacteria [73–77], we hypothesized that the regulated LPS and
capsule changes that are commensurate with host-adaptation
would diminish complement deposition. As shown in Fig 5, MHB-
grown F. tularensis exposed to complement-active normal mouse
serum rapidly accumulated a ,35 kDa C3 fragment (consistent
with the size of C3d) that failed to accumulate on BHI-grown, WT
bacteria. Fragments consistent with the sizes of the a-chain in C3b
(,100 kDa), iC3b1 and iC3b2 (,68 and ,62 kDa) followed a
similar pattern of deposition, albeit with different kinetics (Fig S4).
Detection of these fragments is consistent with the reported ability
of F. tularensis to bind factor H [78] which, in conjunction with
Factor I, cleaves C3b [79]. As expected [73], deposition of
complement was accelerated by the absence of OAg (wbtA strains).
However, the BHI-grown wbtA strain still accumulated less C3d
than MHB grown wbtA – indicating that the non-OAg, HMW
carbohydrate produced by BHI-grown bacteria may also impede
complement deposition. At this time we do not know which
pathway(s) (classical, alternative, mannose-binding lectin) were
active in our assays.
One of the most thoroughly characterized innate cellular
responses to F. tularensis is the TLR2-dependent activation of naı ¨ve
MW resulting in the secretion of TH1 pro-inflammatory cytokines
such as TNF-a and IL1-b [80-83]. Since bacterial lipoproteins
(such as Tul4 - a canonical F. tularensis lipoprotein) are thought to
be the principal agonists for TLR2-mediated activation
[66,67,84], our observation that host-adaptation shields Tul4
from Ab suggested that Ft lipoproteins might also be shielded from
interaction with TLR2. To test this hypothesis, we incubated naı ¨ve
MW with F. tularensis that, through either genetic lesion or different
growth conditions, had differing levels of HMW carbohydrates
and distinct Ab accessibilities to Tul4.
Compared to MHB-grown F. tularensis, bacteria grown in BHI
or MW (both of which have more capsule and less Ab-accessible
Tul4 [Figs 3, 6A+B]) elicited significantly less TNF-a and IL-1b
from bone-marrow derived macrophages (BMDM) (Fig 6C,
p,0.001 for both TNF-a and IL-1b). In the absence of OAg,
Tul4 is more surface-accessible and BMDMs responding to OAg-
deficient bacteria produced significantly more TNF-a and IL-1b
(BHI WT and wbtA, p,0.001 for TNF-a and p,0.05 for IL-1b
Fig 6). Supplementation of BHI with casamino acids (BCA) to the
level found in MHB suppresses many facets of host-adaptation
(Fig 1 and [12]). Here we found that bacteria grown in BCA have
reduced levels of HMW carbohydrate and increased surface-
accessibility of Tul4 compared to their BHI-grown counterparts
(Figs 6A and 6B). Paradoxically, BCA grown bacteria bound more
a-OAg capsule Ab suggesting that the observed reduction of
HMW carbohydrate primarily reflects decreased production of the
non-OAg, putative capsule. The BCA-grown WT F. tularensis also
provoked significantly higher levels of TNF-a and IL-1b from
BMDMs (Fig 6C, p,0.028 for both TNF-a and IL-1b). The
addition of spermine to MHB (MS) has been shown by Carlson et
al to increase transcription of wbtA by F. tularensis and to decrease
TNF-a production by MW responding to MS-grown F. tularensis
LVS and SchuS4 [34]. We found that MS-grown F. tularensis have
slightly longer LPS-OAg, slightly increased levels of HMW
carbohydrate, increased binding of a-OAg capsule Ab, and
reduced accessibility of Tul4 (Fig 6A+B) compared to MHB-
grown bacteria. MS-grown bacteria also evoke significantly less
TNF-a and IL-1b from BMDMs (p,0.001 for both TNF-a and
IL-1b in Figs 6C).
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Previously we reported that mice challenged with BHI-grown F.
tularensis LVS reproducibly succumb to infection ,1 day sooner
than mice challenged with an equivalent dose of MHB-grown
bacteria [12]. At the time, we assumed that this difference was
largely an indication that the host-adapted bacteria were better
prepared for the metabolic/nutritional environment of the
mammalian host. In light of the LPS and capsule changes noted
above, it is likely that the differences in the survival also reflected
the heightened susceptibility of non-adapted bacteria to host
innate immune effectors that could target the bacterium for
clearance before it could host-adapt. Here we sought to extend our
findings with LVS to the human-virulent strain F. tularensis
SchuS4.
We have previously found protein expression by differentially-
grown SchuS4 to follow a pattern similar to that of differentially-
grown LVS [12]. Accordingly, here we examined the carbohy-
drate composition of differentially-grown SchuS4. As shown in
Fig. 7A, two features of BHI-grown LVS are conserved in BHI-
grown SchuS4 – i) an increase in the proportion of LPS molecules
bearing a large number of OAg-repeating units, and ii) an
increase in the size of the HMW carbohydrate. Interestingly,
SchuS4 appears to produce more HMW carbohydrate than LVS.
Next we examined TNF-a and IL-1b production by BMDM
responding to differentially-grown SchuS4. As shown in Fig 7B
and similar to our observations with LVS, BHI-grown SchuS4
elicited significantly lower levels of these pro-inflammatory
cytokines from murine BMDMs and human U937 cells (data
not shown) compared with that provoked by MHB-grown SchuS4
(p,0.001 for both TNF-a and IL-1b from BMDMs).
Finally, we examined survival of C57BL/6 mice challenged
with MHB- or BHI-grown, F. tularensis SchuS4. In our
experience, SchuS4 grows slightly faster than LVS suggesting
that these bacteria might host-adapt more quickly than LVS and
Figure 4. F. tularensis grown in BHI produce a HMW carbohydrate, independent of OAg, which correlates with reduced access of
OMPs to Ab. A) Carbohydrates from the indicated proteinase K-treated samples were visualized as in Fig 2b. B) Ab pulldown assays were
performed as in Fig 3. C) surface-bound Ab to FopA ratios from 3 independent experiments were quantified as in Fig 3. Asterisks indicate values that
differed significantly (p#0.05, Bonferonni-corrected T-test).
doi:10.1371/journal.pone.0022335.g004
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less than was previously observed with LVS [12]. Consistent with
the above predictions and the presumably heightened suscepti-
bility of non-adapted bacteria to the restrictions present in the
host environment (nutritional, innate immune, etc), we observed
(in 3 independent experiments initiated with distinct prepara-
tions of bacteria) that lethality among mice challenged with
MHB-grown SchuS4 began later and took longer to complete
than in mice challenged with BHI-grown bacteria (data not
shown). For the mice infected with BHI-grown SchuS4,
mortality began 5 days (120 hrs) post-infection (PI) with a
median survival time of 132 hrs. By day 6 (144 hrs) PI, all mice
had succumb to infection with BHI-grown bacteria. For the mice
challenged with MHB-grown SchuS4, mortality began at
126 hrs (median survival time =144 hrs) but was not complete
until day 7.25 (174 hrs) PI. The differences in survival of mice
infected with MHB-grown and BHI-grown F. tularensis SchuS4
were highly-significant (p,0.001).
Discussion
We began these studies with the goal of identifying Ab-
accessible OMPs expressed by host-adapted F. tularensis; these
proteins could then be evaluated as subunit vaccine candidates.
Pursuit of this goal led us to the discovery that host adaptation
includes multiple changes to the bacterium’s surface carbohydrates
(LPS and capsules) which cumulatively hinder Ab, complement,
and TLR2-mediated recognition of OM constituents.
Within the mammalian host, F. tularensis undergoes intracellular
replication yet has a significant extracellular phase [5,7] which
likely facilitates dissemination. During this latter phase F. tularensis
is presumably exposed to a variety of anti-bacterial factors such as
complement, antibody, and phagocytes - which if activated – can
hinder the bacterium’s progress [85]. For many pathogens,
significant protection is afforded by a large polymeric capsule
that surrounds the bacterium and limits access of immune effectors
to the bacterium’s limiting membrane [86–88]. In this regard, it is
not surprising that F. tularensis also would utilize this highly
successful strategy. However, the existence and/or composition of
F. tularensis capsule(s) have remained a subject of controversy.
Several electron microscopic (EM) analyses have noted
circumferential labeling of bacteria that had been negatively-
stained with heavy metals or immuno-labeled with a-F. tularensis
sera - thereby providing support for the existence of an F. tularensis
capsule [89,90,76]. In contrast, several recent attempts to detect a
capsular-structure and/or material have been unsuccessful
[73,91,92], prompting speculation that LPS OAg might be the
only capsule-like structure produced by the bacterium [92]. Initial
clues to the resolution of this conceptual discord were provided by
the observation that repeated serial passage of F. tularensis in a
chemically-defined, synthetic medium increased the abundance of
an EM-visible capsule-like material [93]. This finding suggested
that capsule production by F. tularensis might be environmentally
regulated, however, it cannot be excluded that extended passage
led to accumulation of encapsulated variants. Recently Apicella et.
al. provided another advancement by generating a capsule-specific
reagent (mAb 11B7) and utilizing SDS-PAGE to visualize the
Figure 6. F. tularensis surface carbohydrates impact the accessibility of TLR2 ligands and the extent of TLR2-dependent macrophage
activation. F. tularensis LVS WT and wbtA strains were grown in MHB (M), BHI (B), MHB supplemented with spermine (MS), or BHI supplemented with
casamino acids (BCA). A) Bacterial lysates containing 10 mg of protein were treated with proteinase K prior to SDS-PAGE resolution and Emerald Green
staining of carbohydrates. B) Intact bacteria were incubated with anti-Tul4A Ab, washed and probed for IgG heavy chain by western blot to detect
surface-bound (S.) a–Tul4A Ab. The probed membranes were stripped and re-probed for the total FopA and total Tul4. C) Viable F. tularensis were
incubated with C57BL/6 BMDMs at an MOI of 100 for 24 hrs prior to analysis of secreted cytokine levels shown as means and standard errors.
doi:10.1371/journal.pone.0022335.g006
Figure 5. Host-adaptation of F. tularensis reduces complement
activation. MHB- or BHI-grown bacteria were incubated for 10 min or
1 hr with 25% normal mouse serum (NMS) or heat-inactivated (hi) NMS.
Washed bacteria were probed by western blot first with a polyclonal Ab
directed against mouse complement protein C3 and then for the F.
tularensis OMP FopA; the a-C3 Ab was empirically-determined to be
selective for the a-chain of murine C3. Results are representative of
three independent experiments.
doi:10.1371/journal.pone.0022335.g005
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biophysical and immunological approaches, were employed to
determine that F. tularensis produces an OAg capsule that is
physically distinct from that of the LPS OAg. Here we synthesized
these multiple observations and experimental approaches and
found that host-adaptation of F. tularensis increases production of i)
OAg capsule, ii) longer polymers of LPS OAg, and iii) an
additional HMW carbohydrate/glycoprotein material(s) with
capsule-like functions. We speculate that the putative glycoprotein
described here may be related to the capsule-like complex, a
putative glycoprotein, recently characterized by Bandara et al
[94]. Collectively these changes shield OM constituents from
recognition by Ab, complement, and TLR2-dependent macro-
phage activation – functions of capsules and/or long LPS which
have been well-characterized in other pathogens [70,71,87,95–97]
which are now beginning to be explored in F. tularensis [73,75].
Our working model for the interactions of differentially-grown F.
tularensis with select immune effectors is presented in Figure 8.
Our results provide both some confirmatory observations and
several novel findings. Perhaps most striking is the marked
induction of multiple capsular-materials and functions that is
commensurate with host-adaptation of F. tularensis (observed with
bacteria grown in MW or BHI). Host-adapted bacteria bound
significantly higher levels of the mAb 11B7 (which labels OAg-
capsule) and contained additional, non-OAg, HMW carbohy-
drates absent in MHB-grown bacteria. The elevated production of
capsule/HMW carbohydrates along with the lengthening of the
LPS OAg polymers correlated with a profound (60-95%)
reduction in the binding of multiple Ab that have reactivity with
OM constituents. These Ab include the polyclonal (p) IgG (but not
IgM) portion of immune sera (raised through sequential infections
with LVS followed by SchuS4) as well as pAb and/or mAb specific
for the lipoprotein Tul4A, the integral OMP FopA, and the LPS
OAg. Interpreting the reduced binding of IMS IgG by host-
adapted F. tularensis is complex in that this sera has a broad range
of specificities that likely include capsule(s) as well as Tul4, FopA,
LPS OAg and many others. However, since Tul4, FopA and LPS
are immuno-dominant Ags [29,32,64], and capsule is reported to
be poorly-immunogenic [90], our observation (that host-adapted
[capsule-expressing] bacteria bind less IMS IgG) is consistent with
an increased amount of poorly-immunogenic capsule blocking
access of Ab to the more highly immunogenic OM moieties. The
use of WT and OAg-mutant bacteria allowed us to conclude that
both the OAg and non-OAg HMW carbohydrates inhibit Ab
binding. However, based on our findings, we can not dissect the
relative contributions of i) the OAg capsule and ii) the longer LPS
OAg polymers to the shielding of OM moieties from Ab.
The results with the mono-specific Abs are most readily
interpreted as an indication that elevated capsule production
limits access of Ab to Ag. Alternatively, host-adapted bacteria
could have increased production (or acquisition) of a protease that
cleaves bound Ab. Indeed F. tularensis has been reported to bind
exogenously-added, active plasmin [98,99] which, in one report,
cleaved both bound, opsonizing IgG and unbound, non-specific
IgG [99]. For several reasons (in addition to the fact that we did
not add plasmin) we conclude that proteolysis of Ab is not the
mechanism underlying the differences we observed. First, while
the amount of bound IgG specific for OM constituents (a-Tul4, a-
FopA, a-LPS OAg) was reduced in host-adapted bacteria, the
amount of surface-bound IMS-IgM was unchanged and the
amount of bound IgG specific for another constituent (a-OAg
capsule) was increased. Secondly, the reduction in binding of a–
OMP Ab (a-Tul4, a-FopA) by BHI-grown bacteria was largely
negated in bacteria (wbtA) unable to produce intact LPS and OAg
capsule. Lastly, the addition of protease inhibitors to BHI-grown
bacteria did not increase the amount of bound Ab (data not
shown). Accordingly, we conclude that the elevated capsule
production by host-adapted F. tularensis limits the access of Ab to
multiple OM antigens.
While both i) complement activation (and subsequent deposi-
tion), and ii) TLR2 engagement (and subsequent cytokine
production), are more complex processes than Ab binding, we
postulate that the increased capsule present on host-adapted F.
tularensis is also limiting access of these innate immunity molecules
to bacterial OM ligands. Activation of C3 leads to deposition of
C3b that contains an a-chain of ,100 kDa which is covalently-
bound to an acceptor molecule on the bacterial surface. The
cooperative activities of Factors H and I cleave C3b sequentially to
yield a–chain fragments (iC3b1, iC3b2, and C3dg/C3d) of ,68,
,62, and ,40/,35 kDa; these C3b fragments retain the ability
to be bound by complement receptors but do not further promote
the complement cascade [79,100]. In our assays with normal
mouse sera as the source of complement, we observed the above
cascades from activation to C3d (or C3dg) production. However,
this was only observed with MHB-grown WT bacteria and OAg-
deficient F. tularensis. In contrast, host-adapted WT bacteria
showed no evidence of C3 deposition, and BHI-grown, OAg-
deficient bacteria accumulated less C3d/C3dg than their MHB-
grown counter parts. The simplest (although not exclusive)
interpretation of these findings is that the C3-activating moieties
(natural Ab, mannose-binding protein, or targets of the alternative
pathway) are shielded from their ligands(s) by capsule similar to
what we hypothesize for the reduced binding of OM-specific Ab to
host-adapted F. tularensis. It is conceivable that the heightened
sensitivity of MHB-grown bacteria to complement may have
Figure 7. BHI-grown F. tularensis SchuS4 also displays increased
production of HMW carbohydrate(s) and reduced cytokine
elaboration. F. tularensis LVS (WT and wbtA) and SchuS4 were grown
in MHB (M) and BHI (B). A) Proteinase K-treated lysates were resolved
through 8-16 % SDS-PAGE Protean II large gels and stained with
Emerald green to visualize carbohydrates. B) Viable F. tularensis SchuS4,
grown as indicated, were co-incubated with C57BL/6 BMDMs at an MOI
of 100 for 24 hrs prior to analysis of secreted cytokine levels. Results are
means and standard errors from three independent experiments each
conducted in duplicate.
doi:10.1371/journal.pone.0022335.g007
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grown F. tularensis that we report here for strain SchuS4 and
observed previously with strain LVS [12].
Theactivation ofnaı ¨veMWsinvitrobyMHB-grownbacteriahas
been shown by multiple groups to be TLR2-dependent and to
characteristically culminate in the elaboration of TH1-type pro-
inflammatory cytokines [80-83]. However, these cytokines are
largely undetectable in the lungs of mice during early respiratory
tularemia (days 0 to ,3) even though this is a time and site of
exponential bacterial replication. This apparent discord has
prompted the notion that the bacterium is actively suppressing the
inflammatory response. The active-suppression hypothesis is
consistent with the observations of many that F. tularensis-infected
cells and/or animals show blunted TH1-type pro-inflammatory
responses to exogenous TLR agonists [101–104]. Active-suppres-
sion of host-cell responses by bacteria is typically mediated by
bacterial effector proteins which are delivered to the host cell
cytoplasm by either a bacterial syringe-like apparatus (T3SS and
T4SS) or as the cargo components of AB-toxins. F. tularensis is
notable for its non-proinflammatory LPS, its lack of identifiable
toxinsand itslackofT3SSandT4SSsyringe-likeapparatuses[105];
a related species F. novocida may have a functional T6SS [106].
Our findings - that host-adapted bacteria produce sufficient surface
carbohydrates to shield known TLR2 ligands (such as Tul4A) from
Ab, and apparently from TLR2, - suggest a distinct mechanism to
explain the apparent hypo-responsiveness of MWs engaging F.
tularensis. Specifically we postulate that host-adapted bacteria, through
shielding of TLR2 ligands with abundant capsular carbohydrates,
either i) simply fail to trigger the TLR2 signaling cascade that results
in production of TNF-aand IL-1b, and/or ii)preferentially engage a
distinct receptor that provokes an non-TH1 type response. Along
these lines, the mannose-receptor, which has been implicated in the
phagocytosis of F. tularensis by MWs and suggested to be a ‘‘safe portal
of entry’’ [107,108], is an attractive candidate as pathogen-mediated
ligation of this receptor can blunt TLR-driven TH1-type pro-
inflammatory responses [109]. We envision that the mannose
receptor could be preferentially engaged by the abundant HMW
carbohydrate capsule present on host-adapted bacteria. An early
analysis of total capsular material (presumably containing both OAg
capsule and non-OAg capsule) detected high levels of mannose [90]
whilearecentanalysisofpurifiedOAgcapsulerevealedanabsenceof
mannose [30]. These observations would be consistent with the non-
OAg capsule (enriched on host-adapted bacteria) being the
presumptive ligand of the mannose receptor. It is conceivable that
earlier and/or more extensive engagement of the mannose receptor,
combined with reduced TLR2 engagement, may have contributed to
the more rapid demise we observed with mice infected with BHI-
grown SchuS4.
Figure 8. A model of the interaction of MHB-grown and host-adapted F. tularensis with select mammalian immune effectors. The
cellular locations depicted for FopA, Tul4, Pal, and FsaP are based upon data in figure 2A and the relevant text in which this data is discussed. The
depiction of host-adapted bacteria having longer LPS O-Ag carbohydrate chains and elevated levels of capsular material is based upon results in
figures 2B, 3, 4, 6A, 7A, S2, and S3. The depiction of antibodies binding differentially to host-adapted and non-adapted bacteria is based on results
presented in figures 3, 4, and 6. The differential binding/activation of complement protein C3 is based upon data in figures 5 and S4. Our model of
TLR2-dependent production of TH1-type pro-inflammatory cytokines by macrophages responding to F. tularensis is based upon results presented in
figures 6B and 7B.
doi:10.1371/journal.pone.0022335.g008
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primarily as tools to explore the impacts of capsule production on
immune effector functions, we believe that our results also have
implications for understanding the regulation of capsular compo-
nents during the host-cell infection cycle. Within the cytoplasm of
mammalian host cells the concentrations of both free amino acids
and spermine are high compared to those of the extracellular
environment. We have shown previously [12], and confirmed
here, that BHI-grown F. tularensis and extracellular, host-adapted
bacteria (those which have emerged from infected MW) are
phenotypically indistinguishable; much of this MglA-dependent
phenotype is repressible by high concentrations of free amino
acids. Using microarrays, RT-PCR, and transcriptional reporters
to compare F. tularensis grown in MHB and MS or harvested from
the cytoplasm of infected cells, Carlson et al [34] found that MS-
grown and intracellular bacteria are highly similar; spermine
activates promoters within multiple insertion sequences including
one upstream of wbtA – thought to be involved with the production
of OAg. Here we found that, compared to bacteria grown in
MHB, MS-grown F. tularensis have increased binding of mAb
specific for the OAg-capsule (shown in Fig 6). We also found that
production of OAg capsule was also stimulated by high
concentrations of free amino acids. The responsiveness of OAg
capsule to spermine and amino acids suggests that the OAg
capsule is important, not only for extracellular survival, but also for
intracellular growth. Indeed Lindemann et. al. have recently shown
that mutants with defects in production and/or export of OAg
capsule, in addition to being complement sensitive, have impaired
cytosolic replication despite showing normal phagosome-escape
[75].
In contrast to the OAg capsule, we believe that one-or-more of
the non-OAg capsular materials is repressed by high concentra-
tions of free amino acids possibly suggesting a primarily
extracellular role for this material. We found that addition of
casamino acids to BHI decreased the production of HMW
carbohydrate by F. tularensis and that this decrease was not
attributable to changes in OAg (shown in Fig 6). We speculate that
this amino-acid inhibitable, extracellular HMW carbohydrate(s)
that we observed maybe similar to the putative capsule noted by
Golovliov et. al. [89]. This material was abundant on extracellular
bacteria yet markedly reduced/absent on intracellular bacteria.
Down-modulation of this non-OAg capsular component once
inside the host cell could facilitate more rapid host-pathogen
interactions such as nutrient acquisition. In the extracellular milieu
this capsular component could impede recognition by comple-
ment, Ab, and TLR2. We postulate that the higher level of capsule
(OAg and non-OAg) present on BHI-grown F. tularensis may have
contributed to the more rapid demise we observed of mice infected
with BHI-grown SchuS4 (this work) and LVS [12].
The survival times we observed for C57Bl/6 mice challenged
with ,20 CFU of MHB-grown SchuS4 (median survival time - 6
days) are highly similar that those recently reported by Ireland et al
in which Balb/c mice were challenged with 25 CFU of MHB-
grown SchuS4 (mean time-to-death of 5.8 and 5.4 days in separate
experiments) [110]. On the other hand, the statistically significant
differences we observed between mice challenged with MHB- and
BHI-grown SchuS4 (median survival time - 12 hr difference, time-
to-complete lethality - 30 hr difference) are similar to differences
recently reported by groups examining the virulence of genetically
distinct F. tularensis type A strains. Molins et al monitored survival
of mice challenged with different clades of type A strains and
observed mean time-to-death differences of 9 hr (between A1a
strains and A2 strains) and 13.5 hrs (between A1a strains and A1b
strains) [111]. Other groups have examined survival of mice
challenged with WT type A strains and isogenic mutants (pilQ,
tolC, rep, hfq, and FTT0609) and found differences in time-to-
complete lethality of 24 hrs [112,113] – similar to the 30 hr
difference we report here for host-adapted vs non adapted SchuS4.
Thus the impact of host-adaptation on murine lethality experi-
ments is similar in magnitude to the bacterial genetic differences
mentioned above.
In addition to the above experiments with mice lacking pre-
existing specific immunity; we predict that the use of host-adapted
or non-adapted challenge inoculums could also impact the
outcome of vaccine efficacy trials. This could be especially true
in the case of OMP-based, sub-unit vaccines - where the
accessibility of the OMPs to Ab differs depending on how the
challenge inoculm was prepared (consider Fig 8). In this case,
vaccine-induced a–OMP Ab (through recruitment of phagocytes
and/or complement) could clear a portion of the challenge
inoculm before the bacteria had host-adapted; after host-
adaptation these Ab would have reduced/no efficacy. In total,
such an experiment could report the vaccine to be ‘‘partially
protective’’ when in fact this might be true only for a MHB-grown
challenge dose. Infection with F. tularensis emanating from a tick,
tabanid fly, mosquito, aerosolized lagomorph, or the ‘‘lab’’ of a
terrorist that does not use MHB could proceed unhindered in the
face of such vaccine-induced immunity. Accordingly, we suggest
that vaccine discovery and testing should incorporate the use of
host-adapted F. tularensis to avoid re-trekking the OspA path.
Materials and Methods
Bacteria and Media
Wild-type (WT) F. tularensis LVS and the isogenic mutant strains
mglA, pmrA, and wbtA have been described previously [12,36,114].
F. tularensis SchuS4, originally isolated from a human case of
tularemia, was obtained from the U.S. Army Medical Research
Institute for Infectious Diseases (Frederick, MD). All experiments
using SchuS4 were conducted within the Albany Medical College
ABSL-3/BSL-3 facility which has been certified by the Center for
Disease Control. SchuS4 lysates for protein analysis to be
performed outside of this facility were generated by boiling
harvested bacteria in 50 mM Tris, pH 8.0 containing 1 % SDS
followed by sterility testing. Escherichia coli WAM 1824, which
secretes a-hemolysin (HylA), has been described [50].
Routine culturing of F. tularensis involved streaking aliquots of
frozen bacterial glycerol stocks onto Mueller Hinton Chocolate
agar plates [Becton, Dickinson and Company (BD), Sparks, MD]
followed by 2–3 days of growth in a humidified chamber
maintained at 37uC. Starter cultures were generated by resus-
pending several isolated colonies in ,100 ml of BHI from which
,50 ml was immediately used to inoculate 3–5 mls of BHI and
MHB for ,18 hrs of growth on an orbital shaker operating at
200 rpm and 37uC. Mature starter cultures were used at a 1:100
dilution to inoculate larger volumes (10–50 ml within 125–250 ml
Erlenmeyer flasks) of fresh media appropriate for each experiment.
Unless stated otherwise, all bacterial cultures used in this work
were in mid-log phase (OD600=0.4–0.6). Preparation of MHB
and BHI media as well as supplementation of BHI with casamino
acids has been described previously [12]. Supplementation of
MHB with spermine to 200 mM was performed as described [34].
Tissue Culture
Unless stated otherwise, tissue culture was performed using
high-glucose DMEM (HyClone. Logan, Utah) containing 10%
fetal bovine serum (Pel-Freez. Rogers, AK), 100 U/ml penicillin/
100 mg/ml streptomycin (Gibco/Invitrogen. Grand Island, NY),
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Herdon VA), 0.075 % sodium bicarbonate (Mediatech), and
50 mM b-mercaptoethanol (Sigma). Bone-marrow-derived macro-
phages (BMDM) were harvested from C57/BL6 mice (Taconic
Farms, NY); the murine macrophage-like cell line RAW 264.7 was
cultured as described [33]. Murine hybridomas producing mAb
directed against IglB and IglC were graciously provided by Francis
Nano (U. of Victoria).
Generation of macrophage-grown bacteria
To generate macrophage (MW)-grown F. tularensis LVS,
adherent RAW cells at ,75 % confluence within four-to-six T-
75 flasks were rinsed and replenished with antibiotic-free DMEM
media (13 ml/flask). MHB-grown bacteria were harvested by
centrifugation (4000 x g, 10 min) and resuspended in 1 ml of
antibiotic-free DMEM media. MW infections were initiated at an
MOI of 500 and allowed to proceed for 8 hrs within a tissue-
culture incubator. Monolayers were rinsed and incubated for 1 hr
with DMEM containing 50 mg/ml gentamicin. Following five
further rinses, the cultures were replenished with fresh antibiotic-
free DMEM prior to further incubation. At 36 hrs post-infection,
the extracellular bacteria present in the tissue-culture supernatant
were subject to 2–4 low-speed (500 x g, 10 min) spins to remove
any MW; supernatants from each spin were examined by darkfield
microscopy for contaminating eukaryotic cells. The bacteria
present in the MW-free supernatants were harvested by centrifu-
gation (7000 x g, 10 min) and gently resuspended to ,5610
9/ml
in antibiotic-free DMEM.
SDS-PAGE and western blot analysis
Samples of Francisella [10 mg( ,1610
8 cells)] were mixed with
Laemelli sample buffer and boiled for 10 min prior to resolution
through 4–12 % gradient SDS-PAGE pre-cast gels (Invitrogen).
The running buffer was NuPAGE MES SDS buffer from
Invitrogen; gels were variously run at 90–160 V. Resolved gels
were stained with either coomassie blue (BioRad) or transferred to
nitrocellulose membranes. Coomassie-stained gels were scanned
into Adobe Photoshop using an HP 2820. Membranes to be
probed with mAb were blocked for 15 min with PBS, 0.05 %
Tween 20, 1% casein; blots to be probed with polyclonal sera were
blocked for 1 hr with PBS, 0.05% Tween 20, 2.5% horse serum,
1% casein. Polyclonal sera were applied for 1–2 hr at dilutions
ranging from 1:1000 to 1:60,000. Supernatants from mAb-
producing hybridomas were applied for overnight (o/n) incuba-
tions. The mAb FB11 specific for F. tularensis O-antigen (Abcam)
was used o/n at a dilution of 1:1000. Blots to be probed multiple
times were first probed with mAb prior to stripping and reprobing
with polyclonal sera. HRP-conjugated secondary antibodies were
used at dilutions ranging from 1:1000 to 1:20,000. Development of
the chemiluminescent substrate (SuperSignal West Pico, Pierce,
Rockford, IL) was visualized using an Alpha Innotech imaging
system in movie mode. Densitometric analysis of developed blots
was performed on the same system.
Antibodies
Primary antibodies were generously provided by Francis E.
Nano (University of Victoria) and Terry Otto (Immuno-Precise
Antibodies, Ltd., a-MglB, a-IglC, a-IglB); Daniel L. Clemens
(University of California Los Angeles, a-GroEL, a-KatG, a-SodB,
and a-Bfr); Micheal V. Norgard and Jason F. Huntley (University
of Texas Southwestern Medical Center, a-Tul4A, a-Mip, a-Pal,
and a-FopA); Eric R. LaFontaine (University of Georgia, a-FspA);
Jorge Benach, Martha Furie, and Anne Savitt (SUNY Stony
Brook, mAb a-Tul4A/LpnA and a-FopA); and Michael Apicella
(University of Iowa, mAb 11B7 a-OAg capsule). Normal mouse
serum (NMS) was collected from naı ¨ve C57/BL6 mice and
prepared in a manner to preserve complement activity. Rabbit
polyclonal sera against the secreted E. coli protein HlyA was
provided by Rodney Welch (University of Wisconsin-Madison).
To generate infection-derived immune mouse sera (IMS) C57/
BL6 mice were sequentially infected with 1000 CFU of LVS
followed 14 days later by 20 CFU of SchuS4. IMS was harvested
11 days post SchuS4 infection, filtered (0.22 mm) and tested for
sterility prior to use. The mAb FB11 specific for F. tularensis O-
antigen was purchased from Abcam. Biotinylated goat a-Ig heavy
(c) chains of mouse, rat, and rabbit IgG or IgM were from
SouthernBiotech (Birmingham Al) and used in western blots O/N
at a dilution of 1:1,000; these primary Ab were detected using
strepavidin-conjugated HRP. FITC conjugated Goat a–mouse C3
was purchased from Immunology Consultants Laboratory. By
comparing the reactivity of this Ab in western blots against whole
NMS prepared in the presence and absence of b–ME we found
that this Ab to be selective for the a-chain of C3.
Fractionation of Francisella
Mid-log phase F. tularensis was harvested by centrifugation (8000
x g, 15 min, 20uC). Supernatants were decanted and sterile
(0.22 mm)-filtered for subsequent analysis; the bacterial pellet was
resuspended in fresh growth media (MHB or BHI), transferred to
pre-weighed Eppendorf tubes, pelleted as above after which the
transfer supernatant was aspirated. Pellet wet weights were
determined and used to estimate cell numbers based upon the
estimate of 1 mg of wet weight =5610
8 bacteria. Cells were
resuspended to 2.5610
7/ml (higher bacterial concentrations
promoted protein precipitation in subsequent steps) in 20 mM
Tris, pH=8.0 containing 100 mM NaCl, 20 ml/ml protease
inhibitor cocktail (Sigma, #P8849). After determining the protein
concentrations (DC protein assay, BioRad, Hercules, CA),
equilibrated bacterial suspensions were supplemented with EDTA
to 5 mM, lysozyme and RNAse to 100 mg/ml each, Benzonase
(1 ml/ml, Sigma), and Triton X-114 (Acros, NJ) to 1% from a 10%
stock in PBS. Following a 1 hr incubation at room temperature
with periodic gentle agitation, a 1/20 vol. aliquot was saved as the
whole-cell (WC) fraction; the WC and remaining sample were
stored at 220uC overnight. The samples were thawed and
incubated at RT until further viscosity reduction abated.
Following 15 min incubation on ice, the samples were centrifuged
(20 min, 16,500 x g,4 uC) to yield Triton X-114 soluble (TxS) and
insoluble (TxI) fractions. The TxS fractions were transferred to
fresh tubes and centrifuged again to remove any TxI carry-over;
the TxI fractions were washed twice with cold PBS (1 vol). The
TxS fractions were incubated in a 32uC water bath for ,10 min
followed by centrifugation (7000 x g, RT, 15 min) to effect phase
partitioning [40–43,64] into aqueous (top) and detergent (bottom)
phases (any protein precipitation at this step rendered the samples
useless, such experiments were discarded). Recovered phases were
washed by supplementation (to 1% Triton X-114 - A or 10 vol
PBS - D) followed by phase separation; three washes per recovered
phase were performed. The washed Triton insoluble (TxI) phases
were resuspended in PBS containing 0.2% sarkosyl (Fisher
Scientific, Fair Lawn, NJ) and incubated for 20 min with gentle
agitation followed by centrifugation (30 min, 4uC, 16,500 x g). The
sarkosyl-soluble (SS) fraction was recovered and centrifuged a
second time to remove any carryover of insoluble material. The
sarkosyl-insoluble (SI) material was washed once with PBS, 0.2%
sarkosyl and dissolved in 10 mM Tris, pH=8.0 containing 1 %
SDS. WC, A, D, SS, and SI fractions were resolved by SDS-
PAGE.
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Boiled samples of F. tularensis in Laemelli sample buffer (1 ug/ul
protein) were de-proteinated with proteinase K (0.4 ug/ul final) at
60uC for 1 hour and re-boiled prior to resolution through 4-12 %
gradient SDS-PAGE pre-cast gels (Invitrogen). Each lane was
loaded with the de-proteinated material generated from F. tularensis
lysate containing 10 ug of protein. Carbohydrates were visualized
in situ using the Pro-Q Emerald 300 Lipopolysaccharide Gel Stain
Kit (Invitrogen) as instructed. Briefly, resolved gels were fixed
over-night in 5% acetic acid, 50% methanol. Following two 20
minute washes in 3% acetic acid, the gels were incubated for 30
minutes in oxidizing solution, washed 3 times in 3% acetic acid
prior to fluorescent staining of oxidized carbohydrates. After two
20 minute washes in 3% acetic acid, the gels were visualized using
a SYBR-green filter and an Alpha Innotech imaging system in
movie mode. Following acquisition of the emerald-green signal,
gels were de-stained overnight in 3% acetic acid and subsequently
stained with SYPRO Ruby fluorescent protein stain (Invitrogen)
and visualized using an ethidium bromide filter as above.
Antibody- and complement-binding assays
To assess binding of Ab or complement to the surface of F.
tularensis, 5610
8 bacteria in 25 ul were mixed with 25 ml of sterile,
pre-cleared (10,000 x g for 10 min) 0.5 X PBS containing 0.1%
glucose and either i) 1–5 ml (empirically-determined) of the test
Ab/sera (sera were heat-inactivated) for Ab-binding assays or ii)
12.5 ml of intact or heat-inactivated normal mouse sera (for
complement-binding assays). To assess the impact of protease
inhibitors on Ab-binding, a protease inhibitor cocktail (Sigma,
p2714 – which includes aprotinin, a plasmin inhibitor) was
included in the above Ab mixture. Samples were Incubated at
37uC for 1.5 hrs (for Ab-binding assays) or for various times
(10 min – 1 hr) for complement-binding assays. Following
incubation, bacteria were pelleted by centrifugation (10,000 x g
for 10 min) and 45 ml of supernatant was removed. The bacteria
were gently resuspended in 1 ml of 0.5 X PBS containing 0.1%
glucose and pelleted by centrifugation (10,000 x g for 10 min) after
which the supernatants were aspirated. Following one additional
wash, the cells were resuspended to 25 ml in 50 mM Tris pH 8.0
containing protease inhibitors followed by the addition of 25 mlo f
sample buffer prior to boiling and SDS-PAGE. 1610
8 bacteria per
lane were resolved by SDS-PAGE and probed for bound
immunoglobulin (IgG or IgM) heavy chain (HC) by western blot.
Following development of the Ig HC signals, we re-probed the
membranes for total FopA and quantified the data as surface Ab/
total FopA and normalized the ratios to the corresponding MHB
result. Statistical analysis was performed with the 2-tailed, T-test
with Bonferonni corrections when appropriate and significance set
at p,0.05. As a control, we included a BHI-grown wbtA strain
[114] since such strains produce neither LPS OAg nor capsular
OAg [30]. Normal mouse serum (NMS) and a-IglC Ab (directed
against a sub-surface protein) were used as control Abs.
Macrophage infections for cytokine analysis
BMDM seeded in 24 or 48 well plates were co-incubated at an
MOI of 100 with F. tularensis that had been grown in vitro (MHB,
BHI, MS, BCA) or harvested from previously-infected BMDM.
After 24 hrs the media was analyzed by ELISA (eBiosciences) to
measure TNF-a and Cytometric Bead Array (BD Pharmingen) to
detect IL-1b. Statistical analysis was conducted using GraphPad
Prism and one-way ANOVA or the Students T-test with
Bonferonni corrections when appropriate and significance set at
p,0.05.
Ethics Statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and all animal work was approved by the Albany
Medical College Animal Care and Use committee (Approval #
901398). Guidelines provided by the NIH were followed in all
experimentation.
Murine infections
We generated two independent sets of matched challenge stocks
(MHB- and BHI-grown F. tularensis SchuS4). Each matched set
was generated from a common pool of single isolated colonies,
picked from a single chocolate ager plate and used to inoculate
both MHB and BHI broth; each broth culture was expanded side-
by-side and harvested at O.D.600=0.2. In three independent
experiments totaling 26–28 mice per media type, groups consisting
of 6–10 C57BL/6 mice, 8–12 wks of age, were anesthetized by
intra-peritoneal injection of 100 ml of xylazine (20 mg/ml) and
ketamine (1 mg/ml) and challenged by intranasal instillation of
,20 CFU of MHB- or BHI-grown F. tularensis SchuS4 in 20 mlo f
PBS. Exact CFUs/inoculum were determined by duplicate plating
of the inoculums at the time of challenge. Mice were monitored
once-to-thrice daily until all mice succumbed to infection (here less
than 8 days). Two of the three experiments used one matched set
of challenge stocks; the other experiment used the other set of
matched challenge stocks. Analysis of the survival data by the Cox
proportional hazard model determined that i) there were no
significant differences among the three experiments (p.0.79) and
ii) the small variation in inoculm size (21–26 CFU) had no
significant impact (p.0.68). This analysis did however find that
inoculum type (MHB- or BHI-grown F. tularensis SchuS4) had a
significant (p=0.0046) impact on survival with a hazard ratio for
BHI-grown bacteria of 2.38 (95% C.I. of 1.31–4.33). This
indicates that at any point in the experiment, a mouse infected
with BHI-grown SchuS4 was 2.4 times more likely to die as a
mouse infected with MHB-grown SchuS4. The observation that
the three experiments were not significantly different also allowed
for analysis of the combined survival data from all 54 mice by the
Kaplan-Meier log-rank test.
Supporting Information
Figure S1 The cellular distribution of the F. tularensis
KatG, GroEL, SodB, and Bfr proteins is markedly
distinct from that of a secreted protein (E. coli HlyA).
F. tularensis LVS and E. coli WAM 1824 cultures grown in MHB
(M) or BHI (B) to mid-log were quantified and harvested by
centrifugation. Sterile-filtered, cell-free supernatants from 5610
9
bacteria were precipitated with 10 volumes of acetone, washed
twice with 70 % ethanol and resuspended in 1% SDS. Cells and
supernatants from the indicated number of bacteria were resolved
by SDS-PAGE and either stained with coomassie blue (top panels)
or analyzed by western blot (lower panels) for the indicated
proteins. Note that the immunoblot signal intensity for MHB-
grown F. tularensis is similar in 10
7 cells and 10
9 supernatant
equivalents indicating that ,1% of each protein is found in the
MHB supernatant. Expression of HlyA is environmentally-
regulated and, in uropathogenic E. coli, is increased during
mammalian infection.
(TIF)
Figure S2 Fractionation of F. tularensis reveals the
presence of an inducible HMW carbohydrate in host-
adapted bacteria. Whole cells (WC) of F. tularensis LVS grown
in MHB (M) or BHI (B) were Tx114 phase-partitioned into
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material was treated with 0.2% sarkosyl (S) resulting in soluble (SS)
and insoluble (SI) fractions. Following proteinase-K treatment and
SDS-PAGE resolution, the samples were stained for carbohy-
drates. Different exposures (top panel-short exposure, bottom
panel- longer exposure) of the same gel are shown here and in
Figure 2B. Western blots with mAb FB11 (specific for LPS OAg,
data not shown) confirmed the identification of the band labeled
‘‘LPS core + 1 OAg unit’’.
(TIF)
Figure S3 F. tularensis grown in BHI produces a both
an OAg and non-OAg HMW carbohydrate and a
,200 kDa putative glycoprotein that partition into the
Tx-114 aqueous phase. Tx114 aqueous phases from MHB
(M)- and BHI (B)-grown F. tularensis WT and wbtA were treated
with proteinase K (PK) and resolved by SDS-PAGE. The resolved
samples were sequentially stained to visualize carbohydrates (left
panel) followed by visualization of protein (right panel). Note that
the bottoms of the loading wells are visible.
(TIF)
Figure S4 Host-adaptation of F. tularensis reduces
complement activation. MHB- or BHI-grown bacteria were
incubated for 10 min or 1 hr with 25% normal mouse serum
(NMS), heat-inactivated (hi) NMS, or in the absence of NMS.
Washed bacteria were probed by western blot with a polyclonal
Ab directed against mouse complement protein C3; the a-C3 Ab
was found to be selective for the a-chain of C3. Results are
representative of three independent experiments.
(TIF)
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